Skip to main content
. Author manuscript; available in PMC: 2022 Dec 15.
Published in final edited form as: Cancer Res. 2022 Jun 15;82(12):2254–2268. doi: 10.1158/0008-5472.CAN-21-3230

Figure 1. MCU overexpression in PDAC correlates with poor patient prognosis and metastatic progression.

Figure 1.

A-B, The expression levels of MCU, MCUb, MICU1, MICU2 and EMRE in resected tumor tissues (T) and paired para-tumor normal tissues (N) from 6 PDAC patients as determined by Western blotting. (B) is densitometry quantitation of data in (A).

C, IHC analysis of PDAC patient tissues showing increased expression of MCU from PanIN to cancer and from PanIN-1 to PanIN-3.

D, IHC staining of MCU expression in normal pancreatic tissue and tumor tissues from PDAC patients (E).

E, The correlation between MCU protein expression levels and overall survival or relapse free survival among a cohort of 132 PDAC patients.

Data in B were analyzed using two-tailed, two sample paired Student’s t-test. * indicated p<0.05.